TG Therapeutics (NASDAQ:TGTX) Reaches New 12-Month High – Should You Buy?

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) hit a new 52-week high during trading on Wednesday . The stock traded as high as $42.36 and last traded at $42.14, with a volume of 1394831 shares traded. The stock had previously closed at $39.88.

Analyst Ratings Changes

Several equities analysts have recently commented on TGTX shares. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. JPMorgan Chase & Co. raised their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, TG Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Stock Up 2.6 %

The firm’s fifty day moving average is $32.89 and its 200 day moving average is $29.50. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a market cap of $6.75 billion, a P/E ratio of -429.86 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insider Buying and Selling

In other news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.50% of the stock is currently owned by company insiders.

Institutional Trading of TG Therapeutics

Institutional investors have recently bought and sold shares of the business. NorthCrest Asset Manangement LLC acquired a new position in shares of TG Therapeutics in the 4th quarter valued at approximately $448,000. Vermillion Wealth Management Inc. bought a new stake in shares of TG Therapeutics in the 4th quarter valued at $30,000. Castleark Management LLC boosted its stake in shares of TG Therapeutics by 25.2% in the 4th quarter. Castleark Management LLC now owns 211,370 shares of the biopharmaceutical company’s stock valued at $6,362,000 after purchasing an additional 42,560 shares during the last quarter. Soleus Capital Management L.P. boosted its stake in TG Therapeutics by 5.8% during the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock worth $80,705,000 after acquiring an additional 146,702 shares in the last quarter. Finally, Wexford Capital LP bought a new position in TG Therapeutics during the fourth quarter worth $421,000. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.